

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJHM1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format.
NEWS 3 MAR 16 CASREACT coverage extended
NEWS 4 MAR 20 MARPAT now updated daily
NEWS 5 MAR 22 LWPI reloaded
NEWS 6 MAR 30 RDISCLOSURE reloaded with enhancements
NEWS 7 APR 02 JICST-EPLUS removed from database clusters and STN
NEWS 8 APR 30 GENBANK reloaded and enhanced with Genome Project ID field
NEWS 9 APR 30 CHEMCATS enhanced with 1.2 million new records
NEWS 10 APR 30 CA/CAPplus enhanced with 1870-1889 U.S. patent records
NEWS 11 APR 30 INPADOC replaced by INPADOCDB on STN
NEWS 12 MAY 01 New CAS web site launched
NEWS 13 MAY 08 CA/CAPplus Indian patent publication number format defined
NEWS 14 MAY 14 RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 15 MAY 21 BIOSIS reloaded and enhanced with archival data
NEWS 16 MAY 21 TOXCENTER enhanced with BIOSIS reload
NEWS 17 MAY 21 CA/CAPplus enhanced with additional kind codes for German patents
NEWS 18 MAY 22 CA/CAPplus enhanced with IPC reclassification in Japanese patents
NEWS 19 JUN 27 CA/CAPplus enhanced with pre-1967 CAS Registry Numbers
NEWS 20 JUN 29 STN Viewer now available
NEWS 21 JUN 29 STN Express, Version 8.2, now available
NEWS 22 JUL 02 LEMBASE coverage updated
NEWS 23 JUL 02 LMEDLINE coverage updated
NEWS 24 JUL 02 SCISEARCH enhanced with complete author names
NEWS 25 JUL 02 CHEMCATS accession numbers revised
NEWS 26 JUL 02 CA/CAPplus enhanced with utility model patents from China

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:28:53 ON 09 JUL 2007

=> file registry
COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 17:29:02 ON 09 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 8 JUL 2007 HIGHEST RN 941671-52-9
DICTIONARY FILE UPDATES: 8 JUL 2007 HIGHEST RN 941671-52-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006



Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10549546.str



chain nodes :

7 8 9 10 12 13 14 24

ring nodes :

1 2 3 4 5 6 11 15 16 17 18

chain bonds :

6-7 7-8 7-13 7-14 8-9 8-24 9-10 10-11 10-12

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 11-15 11-18 15-16 16-17 17-18

exact/norm bonds :

6-7 7-8 7-13 7-14 8-9 8-24 9-10 10-11 10-12 11-15 11-18 15-16 16-17
17-18

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:C,N

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom
24:CLASS

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 17:29:22 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 389 TO ITERATE

100.0% PROCESSED 389 ITERATIONS

29 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**


PROJECTED ITERATIONS: 6597 TO 8963

PROJECTED ANSWERS: 257 TO 903

L2 29 SEA SSS SAM L1

=> d scan

L2 29 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Piperidine, 1-[1-oxo-3-[[1-phenylacetyl][3-(trifluoromethyl)phenyl]sulfonyl
amino]propyl]-4-(phenylmethyl)- (9CI)
MF C30 H33 F3 N2 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l1 full
FULL SEARCH INITIATED 17:30:07 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 7220 TO ITERATE

100.0% PROCESSED 7220 ITERATIONS 492 ANSWERS
SEARCH TIME: 00.00.01

L3 492 SEA SSS FUL L1

=> file caplus	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	172.55	172.76

FILE 'CAPLUS' ENTERED AT 17:30:11 ON 09 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Jul 2007 VOL 147 ISS 3
FILE LAST UPDATED: 8 Jul 2007 (20070708/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3
L4 15 L3

=> d l4 1-15 ibib abs

L4 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 20071259671 CAPLUS
 DOCUMENT NUMBER: 1461297694
 TITLE: Biocompatible cyanine fluorescent imaging agents and method of in vivo optical imaging
 INVENTOR(S): Rajopadhye, Milind; Groves, Kevin
 PATENT ASSIGNEE(S): Vison Medical, Inc., USA
 SOURCE: PCT Int. Appl., 98pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007028163	A1	20070308	WO 2006-US34604	20060901
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, FI, GB, GD, GE, GH, GI, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2005-714075P P 20050902
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB This invention relates to new fluorescent chemical entities that are designed to attach to biocompatible mols. to form in vivo optical imaging agents. The fluorescence intensity of the fluorophore is enhanced upon attachment to the biocompatible mol. Thus, a fluorophore I was synthesized by reacting the N-hydroxysuccinimide ester of corresponding cyanine mol. (1.1mg, 1 μmol) with 3,3-diphenylpropylamine (1.1 mg, 5 μmol) in 115 μL of anhydrous DMF and kept at room temperature for one hour.
 REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 2006:610647 CAPLUS
 DOCUMENT NUMBER: 145:224314
 TITLE: Quantitative structure-activity relationship studies on matrix metalloproteinase inhibitors: hydroxamic acid analogs
 AUTHOR(S): Gupta, S. P.; Kumaran, S.
 CORPORATE SOURCE: Department of Chemistry, Birla Institute of Technology and Science, Pilani, 333031, India
 SOURCE: Medicinal Chemistry (2006), 2(3), 243-250
 CODEN: MCEHAJ; ISSN: 1573-4064
 PUBLISHER: Bentham Science Publishers Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English



AB A quant. structure-activity relation study has been conducted on two different series of acyclic hydroxamic acid analogs acting as matrix metalloproteinase (MMP) inhibitors. The results suggest that in a few cases, the hydrophobic property of the mols. is the major governing factor. However, in some cases, the polarizability of the mols. is shown to be dominant. The two enzymes, MMP-9 and MMP-13, are shown to behave in a similar fashion with any group of inhibitors.
 REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 2005:284145 CAPLUS
 DOCUMENT NUMBER: 142:355177
 TITLE: Preparation of aminoquinolines for treating inflammatory and immune diseases
 INVENTOR(S): Lin, Chu-Chung; Liu, Jen-Fuh; Chang, Chih-Wei; Chen, Shu-Jen; Xiang, Yibin; Cheng, Pei-Chin; Jan, Jiing-Jyh
 PATENT ASSIGNEE(S): Taiwan
 SOURCE: U.S. Pat. Appl. Publ., 26 pp., Cont.-in-part of U.S. Ser. No. 819,646.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005070573	A1	20050331	US 2004-953937	20040929
US 2004209902	A1	20041021	US 2004-819646	20040406
US 7183413	B2	20070227		
AU 2004229404	A1	20041028	AU 2004-229404	20040406
CA 2521619	A1	20041028	CA 2004-2521619	20040406
EP 1613322	A2	20060111	EP 2004-759214	20040406
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR JP 2006522814 T 20061005 JP 2006-509778 20040406 US 2003-462495P P 20030411 US 2004-551750P P 20040309 US 2004-819646 A2 20040406 WO 2004-US10695 W 20040406				

PRIORITY APPLN. INFO.: MARPAT 142:355177
 GI

L4 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
 are cycloalkyl; R3, R4 = H, AN(B)D; R5-R8 = H, alkyl, or halo; A = alkyl optionally contg. 1-6 heteroatoms; B = H, alkyl; D = alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, etc.; or B and D together are heterocycloalkyl or heteroaryl that bind to CXCR3 receptors and therefore are useful for treating inflammatory and immune diseases, were prep. E.g., a multi-step synthesis of 11, starting from 4,6-dichloro-2-methylquinoline, was given. Ninety exemplified compds. 1 were tested for their efficacy in blocking activation of CXCR3 using a DELFIA GFP-binding kit (Wallac Oy, Turku, Finland). Unexpectedly, 51 compds. showed IC50 values lower than 1.0 μM, 22 compds. showed IC50 values between 1 μM and 10.0 μM, and 17 compds. showed IC50 values greater than 10.0 μM. The pharmaceutical compn. comprising the compd. 1 is disclosed.



AB The title compds. 1 [X1-X4 = C; R1, R2 = H, alkyl; or R1 and R2 together

L4 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 2005:241640 CAPLUS
 DOCUMENT NUMBER: 142:463562
 TITLE: Synthesis of 3-Arylpiperidines by a Radical 1,4-Aryl Migration
 AUTHOR(S): Gheorghe, Alexandru; Quiclet-Sire, Beatrice; Vila, Xavier; Zard, Samir Z.
 CORPORATE SOURCE: Laboratoire de Synthèse Organique, Département de Chimie, Ecole Polytechnique, Palaiseau, 91128, Fr.
 SOURCE: Organic Letters (2005), 7(8), 1653-1656
 CODEN: ORLEF7; ISSN: 1523-7060
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 142:463562
 AB A route to 3-arylpiperidines, 3-arylpiperidines, and 5-arylpiperidin-2-ones involving a radical 1,4-aryl migration has been explored. The sequence requires a xanthate addition to an N-allylarylsulfonamide, followed by acetylation and treatment with dilauroyl peroxide to give the 1,4-aryl transfer product, which upon acidic hydrolysis affords the desired piperidine derivative. E.g., reaction of 4-MeC6H4SO2NHCH2CH2 and MeO2CCH2SCSO2Et gave 4-MeC6H4SO2NHCH2CH2(CH2CH2CO2Me). Acetylation and treatment of the latter with dilauroyl peroxide gave the 1,4-aryl transfer product AcNHCH2CH2(C6H4Me-4)CH2CH2CO2Me. 3-Arylpiperidines, 3-arylpiperidines, and 5-arylpiperidin-2-ones were prepared from compds. such as AcNHCH2CH2(C6H4Me-4)CH2CH2CO2Me.
 REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 2003:485895 CAPLUS
 DOCUMENT NUMBER: 139:223711
 TITLE: Novel inhibitors of procollagen C-Proteinase. Part 2: glutamic acid hydroxamates
 AUTHOR(S): Robinson, L. A.; Wilson, D. M.; Delaet, N. G. J.; Bradley, E. K.; Dankwardt, S. M.; Campbell, J. A.; Martin, R. L.; Van Wart, H. E.; Walker, K. A. M.; Sullivan, R. W.
 CORPORATE SOURCE: CombiChem Inc., San Diego, CA, 92121, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(14), 2381-2384
 CODEN: BMCLB; ISSN: 0960-894X
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 139:223711
 AB Glutamic acid derived hydroxamates were identified as potent and selective inhibitors of procollagen C-proteinase, an essential enzyme for the processing of procollagens to fibrillar collagens. Such compds. have potential therapeutic application in the treatment of fibrosis.
 REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 2000:699185 CAPLUS
 DOCUMENT NUMBER: 133:267150
 TITLE: Preparation of amino acid sulfonamide derivatives as inhibitors of aspartyl protease
 INVENTOR(S): Tung, Roger Dennis; Salituro, Francesco Gerald; Deininger, David D.; Murcko, Mark Andrew; Novak, Perry Michael; Bhisetti, Govinda Rao
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals, Incorporated, USA
 SOURCE: U.S., 74 pp., Cont.-in-part of U.S. Ser. No. 207,580, abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6127372	A	20001003	US 1996-424372	19960401
WO 9524385	A1	19950914	WO 1995-US2420	19950224
V: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.: US 1994-207580 B2 19940307 WO 1995-US2420 W 19950224				

OTHER SOURCE(S): MARPAT 133:267150
 AB Sulfonamides Z-(CH2)2pC(G)(CX')N(G')N(D')SO2-E' [Z = N(D), -SO2E, NH-A, N(D)-A, NH-E, NHC(O)N(D)(E), NH-Ht, N(D)-Ht or phthalimidy (A = Ht or -R1-Ht, where Ht is a heterocycle which may be substituted, R1 = CO, SO2, COCO, O2C, OSO2, NHSO2, NHCOC, which may be substituted); D, D' = aryl, carbocycle, Ht, alkyl, alkenyl, cycloalkyl, cycloalkenyl, etc.; m = 1-3; p = 0 or 1; G, G' = H2 or O; X, X' = H, OH, NH2, SH, D, halo or XX' = O] were prepared as aspartyl protease inhibitors. Thus, t-BUNHCON(CH2Ph)CH2CH(OH)N(CH2-cyclopentyl)SO2C6H4OMe-p, prepared by sequential reactions of cyclopentylmethylamine, p-methoxybenzenesulfonyl chloride, epibromohydrin, benzylamine, and t-Bu isocyanate, showed Ki = 2,400 for inhibition of HIV-1 protease.
 REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 2000:441768 CAPLUS
 DOCUMENT NUMBER: 133:74324
 TITLE: Preparation of amino acid sulfonamide hydroxamates as inhibitors of procollagen C-proteinase.
 INVENTOR(S): Billedeau, Roland Joseph; Broka, Chris Allen; Campbell, Jeffrey Allen; Chen, Jian Jeffrey; Dankwardt, Sharon Marie; Delaet, Nancy; Robinson, Leslie Ann; Walker, Keith Adrian; Murray, F. Hoffmann-La Roche A.-G., Switz.
 PATENT ASSIGNEE(S): PCT Int. Appl., 133 pp.
 SOURCE: CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000037436	A1	20000629	WO 1999-EP9920	19991214
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CP, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2355902	A1	20000629	CA 1999-2355902	19991214
BR 9916504	A	20010911	BR 1999-16504	19991214
EP 1149072	A1	20011031	EP 1999-963530	19991214
EP 1149072	B1	20040630		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200101868	T2	20011121	TR 2001-200101868	19991214
HU 200104658	A2	20020629	HU 2001-4658	19991214
JP 2002533322	T	20021008	JP 2000-589508	19991214
AU 769319	B2	20040122	AU 2000-19792	19991214
NZ 512292	A	20040326	NZ 1999-512292	19991214
AT 270271	T	20040715	AT 1999-963530	19991214
RU 2232751	C2	20040720	RU 2001-119461	19991214
US 6492394	B1	20021210	US 1999-469660	19991222
HR 2001000443	A1	20020630	HR 2001-443	20010614
ZA 2001005014	A	20020919	ZA 2001-5014	20010619
MX 2001PA06328	A	20010910	MX 2001-PA6328	20010620
IN 2001CN00859	A	20050304	IN 2001-CN859	20010620
NO 2001003100	A	20010821	NO 2001-3100	20010621
US 2003199520	A1	20031023	US 2002-267292	20021009
US 6844366	B2	20050118		
US 2003216405	A1	20031120	US 2002-267727	20021009
US 6787559	B2	20040907		

PRIORITY APPLN. INFO.: US 1998-113311P P 19981222
 US 1999-147053P P 19990803
 US 1999-164138P P 19991108
 WO 1999-EP9920 W 19991214
 US 1999-469660 A3 19991222
 OTHER SOURCE(S): MARPAT 133:74324
 AB HOMOCOCHEIRNSO2Ar2 [R1 = alkyl, haloalkyl, heteroalkyl, cycloalkyl, aryl, aralkyl, aralkenyl, heteroaryl, heteroaralkyl, aminyl, aryl, aralkyl, etc.; R = CHR2Ar1, CHR2CH:CHAr1; Ar2 = specified (substituted) Ph, naphthyl; R2 = H, alkyl; with provisos], were prepared. Thus, N-hydroxy-2-(R)-[3,4-

L4 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
ACCESSION NUMBER: 1999:761121 CAPLUS
DOCUMENT NUMBER: 131:351674
TITLE: Preparation of N-(arylsulfonyl)valine hydroxamic acids and analogs as matrix metalloproteinase inhibitors or TNF production inhibitors
INVENTOR(S): Robinson, Ralph P.; Rizzi, James P.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S., 18 pp.; CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
PATENT NO. KIND DATE APPLICATION NO. DATE
US 5994351 A 19991130 US 1998-122920 19980727
US 5863949 A 19990126 US 1997-894873 19970804
US 6147074 A 20001114 US 1999-406522 19990928
US 6380219 B1 20020430 US 2000-635186 20000808
PRIORITY APPLN. INFO.: WO 1995-US2679 W 19950307
US 1997-894873 A3 19970804
US 1998-122920 A3 19980727
US 1999-406522 A3 19990928
OTHER SOURCE(S): MARPAT 131:351674
AB .RSO2N[(CH2)nCOX]CR3R4CONHOH [R = (un)substituted (hetero)aryl; R3,R4 = H, OH, alkyl, (hetero)aryl(alkyl), etc.; X = OH, alkoxy, NR1R2, R1,R2 = H, alkyl, (un)substituted piperidyl, etc.; NR1R2 = heterocyclyl] were prepared as matrix metalloproteinase inhibitors or TNF production inhibitors (no data).
Thus, (R)-H2NCH(CHMe2)CO2CH2Ph was amidated by 4-(MeO)CGH4SO2Cl and the product N-alkylated by BrCH2CO2CMe3 to give, after saponification, (R)-4-(MeO)CGH4SO2N(CH2COX)CH(CHMe2)COR5 (I; R5 = OCH2Ph, X = OH) which was converted in 4 addnl. steps to I (R5 = NHOH, X = morpholino).
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:96004 CAPLUS
DOCUMENT NUMBER: 132:151682
TITLE: Preparation of sulfonaminoalkenediamides and related compounds as matrix metalloproteinase inhibitors.
INVENTOR(S): Beckett, Raymond Paul; Martin, Fionna Mitchell; Miller, Andrew; Todd, Richard Simon; Whittaker, Mark
PATENT ASSIGNEE(S): British Biotech Pharmaceuticals Ltd., UK
SOURCE: U.S., 32 pp., Cont.-in-part of Ser. No. Wo97GB-9702891.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:
PATENT NO. KIND DATE APPLICATION NO. DATE
US 6022873 A 20000208 US 1998-121033 19980723
WO 9817655 A1 19980430 WO 1997-GB2891 19971020
W: AU, BR, CA, CN, CZ, DE, GB, GE, HU, IL, JP, KR, MX, NO, NZ, PL, RU, SG, SK, TH, UA, US
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
PT 1030842 T 20030731 PT 1997-912351 19971113
ES 2195122 T3 20031201 ES 1997-912351 19971113
PRIORITY APPLN. INFO.: GB 1996-21814 A 19961019
WO 1997-GB2891 A2 19971020
EP 1997-912351 A 19971113
OTHER SOURCE(S): MARPAT 132:151682
AB VCOC[CH2]nNR3SO2R4[CH]R1COR2 [V = HO, HONH; n = 1-4; R1 = alkyl, alkenyl, alkynyl, perfluoroalkyl, phenylalkyl, heteroarylalkyl, cycloalkylalkyl, etc.; R2 = 5-8 membered (substituted) N-heterocyclyl; R3 = H, alkyl, cycloalkyl, Ac; R4 = (substituted) alkyl, alkenyl, alkynyl, perfluoroalkyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, etc.; R3R4 = (substituted) alkylene, alkenylene, were prepared Thus, 2S-[(4-methoxybenzenesulfonylamino)ethyl]-5-methyl-3R-(piperidine-1-carbonyl)hexanoic acid hydroxamide [prepared from 2S-(2-hydroxyethyl)-3R-isobutylsuccinic acid 4-benzyl ester 1-tert-Bu ester] inhibited human fibroblast collagenase with IC50 = 50 nM.
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:761121 CAPLUS
DOCUMENT NUMBER: 131:351674
TITLE: Preparation of N-(arylsulfonyl)valine hydroxamic acids and analogs as matrix metalloproteinase inhibitors or TNF production inhibitors
INVENTOR(S): Robinson, Ralph P.; Rizzi, James P.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S., 18 pp.; CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
PATENT NO. KIND DATE APPLICATION NO. DATE
US 5994351 A 19991130 US 1998-122920 19980727
US 5863949 A 19990126 US 1997-894873 19970804
US 6147074 A 20001114 US 1999-406522 19990928
US 6380219 B1 20020430 US 2000-635186 20000808
PRIORITY APPLN. INFO.: WO 1995-US2679 W 19950307
US 1997-894873 A3 19970804
US 1998-122920 A3 19980727
US 1999-406522 A3 19990928
OTHER SOURCE(S): MARPAT 131:351674
AB .RSO2N[(CH2)nCOX]CR3R4CONHOH [R = (un)substituted (hetero)aryl; R3,R4 = H, OH, alkyl, (hetero)aryl(alkyl), etc.; X = OH, alkoxy, NR1R2, R1,R2 = H, alkyl, (un)substituted piperidyl, etc.; NR1R2 = heterocyclyl] were prepared as matrix metalloproteinase inhibitors or TNF production inhibitors (no data).
Thus, (R)-H2NCH(CHMe2)CO2CH2Ph was amidated by 4-(MeO)CGH4SO2Cl and the product N-alkylated by BrCH2CO2CMe3 to give, after saponification, (R)-4-(MeO)CGH4SO2N(CH2COX)CH(CHMe2)COR5 (I; R5 = OCH2Ph, X = OH) which was converted in 4 addnl. steps to I (R5 = NHOH, X = morpholino).
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:662331 CAPLUS
DOCUMENT NUMBER: 132:30315
TITLE: The synthesis and biological evaluation of non-peptidic matrix metalloproteinase inhibitors
AUTHOR(S): Martin, Fionna M.; Beckett, R. Paul; Bellamy, Claire L.; Courtney, Paul F.; Davies, Stephen J.; Drummond, Alan H.; Dodd, Rory; Pratt, Lisa M.; Patel, Sanjay R.; Ricketts, Michelle L.; Todd, Richard S.; Tuffnell, Andrew R.; Ward, John W. S.; Whittaker, Mark
CORPORATE SOURCE: British Biotech Pharmaceuticals Limited, Oxford, OX4 5LY, UK
SOURCE: Bioorganic & Medicinal Chemistry Letters (1999), 9(19), 2887-2892
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Novel sulfonamide matrix metalloproteinase inhibitors most with piperidine amide were synthesized by a route involving a stereoselective conjugate addition reaction. Enzyme selectivity was dependent on the nature of the sulfonamide substituents. Several compds. are potent selective collagenase inhibitors with good oral bioavailability.
REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 1999:626184 CAPLUS
 DOCUMENT NUMBER: 131:242793
 TITLE: Preparation of hydroxamic acids and carboxylic acids as metalloproteinase inhibitors
 INVENTOR(S): Beckett, Raymond Paul; Martin, Fionna Mitchell; Miller, Andrew; Todd, Richard Simon
 PATENT ASSIGNEE(S): British Biotech Pharmaceuticals Limited, UK
 SOURCE: PCT Int. Appl., 52 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9948881	A1	19990930	WO 1998-GB914	19980325
W: AU, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, RU, SG, SK, TR				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9868435	A	19991010	AU 1998-68435	19980325
EP 1066273	A1	20010110	EP 1998-913910	19980325
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2003522723	T	20030729	JP 2000-537864	19980325
PRIORITY APPLN. INFO.: WO 1998-GB914 A 19980325				
AB Hydroxamic acids and carboxylic acids, e.g. 2S-[[[5-dimethylaminonaphthalene-1-sulfonyl]methylamino]methyl]-5-methyl-3R-(morpholine-4-carbonyl)hexanoic acid hydroxamide, matrix metalloproteinase inhibitors, were prepared				
REFERENCE COUNT: 3				

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 1998:268494 CAPLUS
 DOCUMENT NUMBER: 128:308398
 TITLE: Preparation of hydroxamides as metalloproteinase inhibitors
 INVENTOR(S): Beckett, Raymond Paul; Martin, Fionna Mitchell; Miller, Andrew; Todd, Richard Simon; Whittaker, Mark
 PATENT ASSIGNEE(S): British Biotech Pharmaceuticals Ltd., UK; Beckett, Raymond Paul; Martin, Fionna Mitchell; Miller, Andrew; Todd, Richard Simon; Whittaker, Mark
 SOURCE: PCT Int. Appl., 70 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9817655	A1	19980430	WO 1997-GB2891	19971020
W: AU, BR, CA, CH, CZ, DE, GB, GE, HU, IL, JP, KR, MX, NO, NZ, PL, RU, SG, SK, TR, UA, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2269283	A1	19980430	CA 1997-2269283	19971020
AU 9747142	A	19980515	AU 1997-47142	19971020
AU 713603	B2	19991209		
GB 2324091	A	19981014	GB 1998-16616	19971020
GB 2324091	B	20001115		
EP 534292	A1	19990811	EP 1997-909461	19971020
EP 934292	B1	20060315		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
NZ 334711	A	20001027	NZ 1997-334711	19971020
JP 2001502348	T	20010220	JP 1998-519112	19971020
AT 320422	T	20060415	AT 1997-909461	19971020
PT 1030842	T	20030731	PT 1997-912351	19971113
ES 2195122	T3	20031201	ES 1997-912351	19971113
ZA 9710611	A	19980612	ZA 1997-10611	19971125
US 6022873	A	20000208	US 1998-121033	19980723
PRIORITY APPLN. INFO.: GB 1996-21814 A 19961019				
EP 1997-912351	A	19971020		
OTHER SOURCE(S): MARPAT 128:308398				
G1				



AB The title compds. [I; V = OH, NHOH; n = 1-4; R1 = Cl-12 alkyl, C2-12

L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
 alkenyl, C2-12 alkynyl, etc.; R2 = (un)substituted 5-8 membered monocyclic or bridged N-heterocyclic ring; R3 = H, Cl-6 alkyl, benzyl, etc.; R4 = Cl-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, etc.; which are matrix metalloproteinase inhibitors and therefore are useful in the treatment of rheumatoid arthritis, osteoarthritis, periodontitis, gingivitis, corneal ulceration, or a neuroinflammatory disorder, were prepd. Thus, multi-step synthesis starting from 2S-(2-hydroxyethyl)-3R-isobutyl-succinic acid 4-benzyl ester 1-tert-Bu ester afforded the title compd. (2S,3R)-II which showed IC50 of ca. 50 nM against human fibroblast collagenase.
 REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 1998:147308 CAPLUS
 DOCUMENT NUMBER: 128:192672
 TITLE: Preparation of arylsulfonylamino hydroxamic acid derivatives as inhibitors of matrix metalloproteinase and production of tumor necrosis factor (TNF)
 INVENTOR(S): Blumenkopf, Todd A.; Robinson, Ralph P.
 PATENT ASSIGNEE(S): Pfizer Inc., USA; Blumenkopf, Todd A.; Robinson, Ralph P.
 SOURCE: PCT Int. Appl., 51 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9807697	A1	19980226	WO 1997-18924	19970725
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU				
RW: GH, HE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CH, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2264284	A1	19980226	CA 1997-2264284	19970725
AU 974563	A	19980306	AU 1997-34563	19970725
AU 711585	B2	19991014		
EP 922030	A1	19990616	EP 1997-930699	19970725
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
BR 9711223	A	19990817	BR 1997-11223	19970725
CN 1228083	A	19990508	CN 1997-197354	19970725
JP 2000501423	T	20000208	JP 1998-510535	19970725
TW 397823	B	20000711	TW 1997-86112058	19970820
US 6153609	A	20001128	US 1999-242504	19990216
NO 9900821	A	19990223	NO 1999-821	19990222
PRIORITY APPLN. INFO.: US 1996-24675P P 19960823				
WO 1997-18924	W	19970725		
OTHER SOURCE(S): MARPAT 128:192672				

AB The title compds. HONHC(O)C(R3)(R4)N(SO2)O(CH2)nC(O)X [I; n = 1-6; X = OR1; R1 = piperidinyl, piperazinyl, indolinyl, etc.; R3, R4 = H, Cl-6 alkyl, CF3, etc.; R3R4 = C3-6 cycloalkyl, oxacyclohexyl, indanyl, etc.; O = Cl-6 alkyl, C6-10 aryl, C5-9 heteroaryl, etc.] and their salts, useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, macular degeneration, rstenosis, periodontal disease, epidermolysis bullosa, scleritis, and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of TNF, were prepared. In addition, the compds. I may be used in combination therapy with standard non-steroidal anti-inflammatory drugs (NSAID'S) and analgesics, and in combination with cytotoxic drugs such as adriamycin, daunomycin, cis-platinum, etoposide, taxol, taxotere and other alkaloids, such as vincristine, in the treatment of cancer. Thus, the 8-step detailed synthesis of compound I [X = 4-[(tert-butylcarbonyl(methylamino)piperidin-1-yl]; n = 2; O = 4-(MeO)C6H4; R3 = H; R4 = cyclohexyl] is described.
 Compds. I are effective at 0.3-5 mg/kg/day.
 REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 1996:632249 CAPLUS
 DOCUMENT NUMBER: 125:276574
 TITLE: Preparation of (arylsulfonylamino)hydroxamates as matrix metalloproteinase and tumor necrosis factor production inhibitors
 INVENTOR(S): Robinson, Ralph P.; Rizzi, James P.
 PATENT ASSIGNEE(S): Pfizer Inc., USA
 SOURCE: PCT Int. Appl., 69 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9627583	A1	19960912	WO 1996-US2679	19960307
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
BW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GN				
IL 117343	A	20020814	IL 1996-117343	19960304
CA 2214720	A1	19960912	CA 1996-2214720	19960307
CA 2214720	C	20040127		
AU 9650293	A	19960923	AU 1996-50293	19960307
AU 707510	B2	19990715		
ZA 9601876	A	19970916	ZA 1996-1876	19960307
EP 813520	A1	19971229	EP 1996-907134	19960307
EP 813520	B1	20011219		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
BR 9607362	A	19971230	BR 1996-7362	19960307
CN 1181066	A	19980506	CN 1996-193213	19960307
CN 1122662	B	20031001		
HU 9800462	A2	19980728	HU 1998-462	19960307
JP 11501910	T	19990216	JP 1996-526918	19960307
JP 3753737	B2	20060308		
RU 2145597	C1	20000220	RU 1997-116727	19960307
AT 211131	T	20020115	AT 1996-907134	19960307
PT 813520	T	20020429	PT 1996-907134	19960307
ES 2169794	T3	20020716	ES 1996-907134	19960307
PL 184158	B1	20020930	PL 1996-322131	19960307
CZ 291106	B6	20021211	CZ 1997-2782	19960307
FI 9703613	A	19971105	FI 1997-3613	19970905
NO 9704103	A	19971105	NO 1997-4103	19970905
NO 913752	B1	20021125		
CN 1316419	A	20011010	CN 2001-111743	20010323
PRIORITY APPLN. INFO.:			US 1995-401049	A1 19950308
OTHER SOURCE(S):			WO 1996-US2679	W 19960307
GI				



AB HONHOCR3R4N(SO2R) (CH2)nCOX [R = (hetero)aryl; R3, R4 = H, alkyl, CF3, (hetero)aryl, etc.; X = OH, alkoxy, NR1R2; R1, R2 = H, alkyl, piperidyl, (hetero)aryl, etc.; NR1R2 = heterocyclyl; n = 1-6] were prepared as matrix metalloproteinase and tumor necrosis factor production inhibitors (no data). Thus, D-Me2CHCH(NH2)CO2CH2Ph was successively N-substituted by 4-(MeO)C6H4SO2Cl and BrCH2CO2CHMe3 and the saponid, product amidated by morpholine to give, in 3 addnl. steps, title compound (R)-I (R3 = CHMe2).

ACCESSION NUMBER: 1995:994876 CAPLUS
 DOCUMENT NUMBER: 124:116874
 TITLE: Preparation of sulfonamide derivatives as aspartyl protease inhibitors
 INVENTOR(S): Tung, Roger Dennis; Salituro, Francesco Gerald; Deininger, David D.; Murcko, Mark Andrew; Novak, Perry Michael; Bhisetti, Govinda Rao
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals Inc., USA
 SOURCE: PCT Int. Appl., 211 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9524385	A1	19950914	WO 1995-US2420	19950224
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2183653	A1	19950914	CA 1995-2183653	19950224
AU 9519332	A	19950925	AU 1995-19332	19950224
AU 699483	B2	19981203		
EP 749421	A1	19961227	EP 1995-911960	19950224
EP 749421	B1	19990915		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1146201	T	19970326	CN 1995-192473	19950224
JP 10500938	T	19980127	JP 1995-523497	19950224
AT 184594	T	19991015	AT 1995-911960	19950224
ES 2139195	T3	20000201	ES 1995-911960	19950224
ZA 9501688	A	19951211	ZA 1995-1688	19950301
IN 1995CA00242	A	20050304	IN 1995-CA242	19950306
US 6127372	A	20001003	US 1996-424372	19960401
HK 1012622	A1	20000922	HK 1998-113972	19981217
GR 3032151	T3	20000427	GR 1999-403237	19991215
PRIORITY APPLN. INFO.:			US 1994-207580	A 19940307
OTHER SOURCE(S):			WO 1995-US2420	W 19950224
GI				





AB Z(CHD)PC(G)(COX')mC(G')ND'SO2E' [D, D' = aryl, heterocyclyl, NH2, alkyl, etc.; E, E' = OH, NH2, aryl, heterocyclyl, etc.; G, G' = H2, O, X, X' = H, oh, NH2, halo, etc.; XX' = O, 2 = NDSO2E, NHA, NHE, heterocyclyl, etc.; A

L4 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
= H, (cyclo)alkyl, Ph, heterocyclyl, etc.; m = 1-3; p = 0 or 1] were
prepd. Title compd. 1 had Ki of 7nM against HIV-1 protease.

=> d 14 1-15 hitstr

L4 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
 IT 928031-23-6P 928031-25-8P 928031-27-0P
 928031-31-6P 928031-35-0P
 RI: DGN (Diagnostic use); IMF (Industrial manufacture); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (production of biocompatible fluorescent imaging agents for in vivo optical imaging)
 RN 928031-23-6 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED
 CH 1
 CRN 928031-22-5
 CMF C63 H73 N5 O15 S5




CH 2
 CRN 121-44-8
 CMF C6 H15 N



RN 928031-25-8 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED
 CH 1
 CRN 928031-24-7
 CMF C64 H75 N5 O15 S5


L4 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 PAGE 1-B





CH 2
 CRN 121-44-8
 CMF C6 H15 N



RN 928031-31-6 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED
 CH 1
 CRN 928031-30-5
 CMF C62 H70 N4 O16 S5




L4 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




CH 2
 CRN 121-44-8
 CMF C6 H15 N



RN 928031-27-0 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED
 CH 1
 CRN 928031-26-9
 CMF C64 H70 N6 O16 S5





L4 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 PAGE 1-B



CH 2
 CRN 121-44-8
 CMF C6 H15 N



RN 928031-35-0 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED
 CH 1
 CRN 928031-34-9
 CMF C61 H68 N4 O15 S5



CH 2

CRN 121-44-8
CMF C6 H15 N



IT 206553-57-3 206553-72-2 244296-01-3

244296-09-1 244296-22-8 244296-25-1


RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)

(QSAR studies of hydramic acid analogs on matrix metalloproteinase inhibitors)

RN 206553-57-3 CAPLUS

CN 1-Piperidinebutanamide, N-hydroxy- α -[[[(4-methoxyphenyl)sulfonyl]methylamino]methyl]- β -(2-methylpropyl)- γ -oxo-, (aR, bR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 206553-72-2 CAPLUS

CN 1-Piperidinebutanamide, α -[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy- β -(2-methylpropyl)- γ -oxo-, (aR, bR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 244296-01-3 CAPLUS

CN 1-Piperidinebutanamide, β -(cyclopentylmethyl)-N-hydroxy- α -[[[(4-methoxyphenyl)sulfonyl]methylamino]methyl]- γ -oxo-, (aR, bR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 244296-09-1 CAPLUS

CN 1-Piperidinebutanamide, β -(cyclopentylmethyl)- α -[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy- γ -oxo-, (aR, bR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 244296-22-8 CAPLUS

CN 1-Piperidinebutanamide, α -[[[(4-chlorophenyl)sulfonyl]methylamino]methyl]- β -(cyclopentylmethyl)-N-hydroxy- γ -oxo-, (aR, bR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 244296-25-1 CAPLUS

CN 1-Piperidinebutanamide, β -(cyclopentylmethyl)-N-hydroxy- α -[[[methyl(1-naphthalenyl)sulfonyl]amino]methyl]- γ -oxo-, (aR, bR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
 IT 849110-84-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of aminoquinolines for treating inflammatory and immune diseases)
 RN 849110-84-5 CAPLUS
 CN Piperidine, 1-[3-[[2-[(6-chloro-2-methyl-4-quinolinyl)amino]ethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 2-A




L4 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
 IT 851461-08-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and radical 1,4-aryl migration reaction of)
 RN 851461-08-0 CAPLUS
 CN Carbonodithioic acid, S-[1-[[[acetyl[(4-bromophenyl)sulfonyl]amino]methyl]-4-oxo-4-(1-piperidinyl)butyl] O-ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
 IT 279254-86-3P 279254-91-0P 279254-97-6P
 279255-03-7P 279255-56-0P 279255-58-2P
 591766-09-5P 591766-10-8P 591766-11-9P
 591766-12-0P 591766-13-1P 591766-14-2P
 591766-15-3P 591766-16-4P 591766-17-5P
 591766-18-6P 591766-19-7P 591766-20-0P
 591766-21-1P 591766-22-2P 591766-23-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation and structure-activity relationship of glutamic acid hydroxamates as novel inhibitors of procollagen C-Proteinase)
 RN 279254-86-3 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[(4R)-4-[(1,3-benzodioxol-5-ylmethyl)][(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-5-(hydroxyamino)-1,5-dioxopentyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 279254-91-0 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[(4R)-4-[(1,3-benzodioxol-5-ylmethyl)][(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-5-(hydroxyamino)-1,5-dioxopentyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 279254-97-6 CAPLUS
 CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)][(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-4-phenyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 279255-03-7 CAPLUS
 CN 1-Piperazinepentanamide, 4-acetyl-α-[(1,3-benzodioxol-5-ylmethyl)][(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279255-56-0 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-4-benzoyl-N-hydroxy-δ-oxo-, (αR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 279255-58-2 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-4-(2-furanylcarbonyl)-N-hydroxy-δ-oxo-, (αR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 591766-12-0 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-4-phenyl-, (αR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591766-13-1 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-4-(2-pyridinyl)-, (αR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591766-14-2 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-4-(3-pyridinyl)-, (αR)-(9CI) (CA INDEX NAME)




RN 591766-09-5 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-4-(phenylmethyl)-, (αR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591766-10-8 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-4-(2-furanylcarbonyl)-, (αR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591766-11-9 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-4-methyl-δ-oxo-, (αR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591766-15-3 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-4-(2-pyridinylmethyl)-, (αR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591766-16-4 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-4-(3-pyridinylmethyl)-, (αR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591766-17-5 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-4-(3-pyridinylmethyl)-, (αR)-(9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 methoxyphenyl)sulfonyl]amino]-N-hydroxy-8-oxo-4-[(4-pyridinylmethyl)-
 , (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591766-19-6 CAPLUS
 CN 1-Piperazinepentanamide, 4-acetyl-α-[(1,3-benzodioxol-5-ylmethyl)][(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-8-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591766-19-7 CAPLUS
 CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)][(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-4-(methylsulfonyl)-8-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591766-20-0 CAPLUS

L4 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 591766-23-3 CAPLUS
 CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)][(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-4-[(1,3-benzodioxol-5-ylmethyl)sulfonyl]amino]carbonyl]-8-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 1-Piperazinecarboxylic acid, 4-[(4R)-4-[(1,3-benzodioxol-5-ylmethyl)][(4-methoxyphenyl)sulfonyl]amino]-5-(hydroxyamino)-1,5-dioxopentyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591766-21-1 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[(4R)-4-[(1,3-benzodioxol-5-ylmethyl)][(4-methoxyphenyl)sulfonyl]amino]-5-(hydroxyamino)-1,5-dioxopentyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591766-22-2 CAPLUS
 CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)][(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-4-[(4-methoxyphenyl)sulfonyl]amino]carbonyl]-8-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
 IT 172738-38-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of amino acid sulfonamide derivs. as inhibitors of aspartyl protease)

RN 172738-38-4 CAPLUS
 CN 1-Piperazinecarboxylic acid, 3-[(1,1-dimethylethyl)amino]carbonyl]-4-[(3S)-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-oxobutyl]-, phenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN


IT 279254-86-3P 279254-88-5P 279254-89-6P
279254-90-9P 279254-91-0P 279254-92-1P
279254-97-6P 279254-98-7P 279255-01-5P
279255-02-6P 279255-03-7P 279255-15-1P
279255-16-2P 279255-21-9P 279255-25-3P
279255-56-0P 279255-58-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid sulfonamide hydroxamates as inhibitors of procollagen C-proteinase)
RN 279254-86-3 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[(4R)-4-[(1,3-benzodioxol-5-ylmethyl)](4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-5-(hydroxyamino)-1,5-dioxopentyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 279254-86-5 CAPLUS
CN 1-Piperazinepentanamide, N-hydroxy-α-[(4-methoxyphenyl)sulfonyl] [(4-methyl-3-nitrophenyl)methyl]amino]-5-oxo-4-phenyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 279254-89-6 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[(4R)-4-[(1,3-benzodioxol-5-ylmethyl)](4-

L4 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 279254-92-1 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[(4R)-4-[(3-fluorophenyl)methyl]](4-methoxyphenyl)sulfonyl]amino]-5-(hydroxyamino)-1,5-dioxopentyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 279254-97-6 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)](4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-4-phenyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
methoxyphenyl)sulfonyl]amino]-5-(hydroxyamino)-1,5-dioxopentyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279254-90-9 CAPLUS
CN 1-Piperazinepentanamide, 4-acetyl-α-[(3-fluorophenyl)methyl]](4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 279254-91-0 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[(4R)-4-[(1,3-benzodioxol-5-ylmethyl)](4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-5-(hydroxyamino)-1,5-dioxopentyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 279254-98-7 CAPLUS
CN 1-Piperazinepentanamide, α-[(3-fluorophenyl)methyl]](4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-4-(2-pyridinyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 279255-01-5 CAPLUS
CN 1-Piperazinepentanamide, α-[(3-fluorophenyl)methyl]](4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-4-(2-pyridinyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 279255-02-6 CAPLUS
CN 1-Piperazinepentanamide, 4-acetyl-α-[(3-fluorophenyl)methyl][(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 279255-03-7 CAPLUS
CN 1-Piperazinepentanamide, 4-acetyl-α-[(1,3-benzodioxol-5-ylmethyl][(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 279255-21-9 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl][(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-4-(phenoxyacetyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 279255-25-3 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl][(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-N-hydroxy-4-(methylsulfonyl)-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 279255-15-1 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl][(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-N-hydroxy-4-[(3-methylphenyl)amino]carbonyl]-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 279255-16-2 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl][(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-N-hydroxy-4-[(3-methylphenyl)amino]carbonyl]-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 279255-56-0 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl][(4-methoxyphenyl)sulfonyl]amino]-4-benzoyl-N-hydroxy-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279255-58-2 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl][(4-methoxyphenyl)sulfonyl]amino]-4-(2-furanylcarbonyl)-N-hydroxy-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 206553-54-0P 206553-55-1P 206553-57-3P
 206553-63-1P 206553-64-2P 206553-66-4P
 206553-67-5P 206553-68-6P 206553-70-0P
 206553-72-2P 206553-74-4P 206553-75-5P
 206553-76-6P 206553-77-7P 206553-78-8P
 206553-81-3P 244296-01-3P 244296-06-8P
 244296-07-9P 244296-09-1P 244296-10-4P
 244296-16-0P 244296-17-1P 244296-22-8P
 244296-23-9P 244296-25-1P 244296-26-2P
 244296-27-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of sulfonylaminoalkanediamides and related compds. as matrix metalloproteinase inhibitors)

RN 206553-54-0 CAPLUS

CN 1-Piperidinebutanamide, N-hydroxy- α -[3-[(4-methoxyphenyl)sulfonyl]methylamino]propyl]- β -(2-methylpropyl)- γ -oxo-, (aS, BR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 206553-55-1 CAPLUS

CN 1-Piperidinebutanamide, N-hydroxy- α -[2-[(4-methoxyphenyl)sulfonyl]methylamino]ethyl]- β -(2-methylpropyl)- γ -oxo-, (aS, BR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 206553-57-3 CAPLUS

CN 1-Piperidinebutanamide, N-hydroxy- α -[[(4-methoxyphenyl)sulfonyl]methylamino]methyl]- β -(2-methylpropyl)- γ -oxo-, (aR, BR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 206553-63-1 CAPLUS

CN 1-Piperidinebutanamide, α -[[(4-butoxyphenyl)sulfonyl]methylamino]methyl]-N-hydroxy- β -(2-methylpropyl)- γ -oxo-, (aR, BR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 206553-64-2 CAPLUS

CN 1-Piperidinebutanamide, α -[[(2-chloro-5-(trifluoromethyl)phenyl)sulfonyl]methylamino]methyl]-N-hydroxy- β -(2-methylpropyl)- γ -oxo-, (aR, BR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 206553-66-4 CAPLUS

CN 1-Piperidinebutanamide, α -[[(4-chloro-2,5-dimethylphenyl)sulfonyl]methylamino]methyl]-N-hydroxy- β -(2-methylpropyl)- γ -oxo-, (aR, BR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 206553-67-5 CAPLUS

CN 1-Piperidinebutanamide, α -[[(2,5-dimethoxyphenyl)sulfonyl]methylamino]methyl]-N-hydroxy- β -(2-methylpropyl)- γ -oxo-, (aR, BR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 206553-68-6 CAPLUS

CN 1-Piperidinebutanamide, N-hydroxy- β -(2-methylpropyl)- α -[methyl(8-quinolinyl)sulfonyl]amino]methyl]- γ -oxo-, (aR, BR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 206553-70-0 CAPLUS


CN 1-Piperidinebutanamide, α -[[(4-chlorophenyl)sulfonyl]methylamino]methyl]-N-hydroxy- β -(2-methylpropyl)- γ -oxo-, (aR, BR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 206553-72-2 CAPLUS
CN 1-Piperidinebutanamide, α-[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 206553-74-4 CAPLUS
CN 1-Piperidinebutanamide, N-hydroxy-α-[[methyl(2-naphthalenylsulfonyl)amino]methyl]-β-(2-methylpropyl)-γ-oxo-, (αR,βR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 206553-75-5 CAPLUS
CN 1-Piperidinebutanamide, α-[[[3,4-dichlorophenyl]sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR) - (9CI) (CA INDEX NAME)




RN 206553-81-3 CAPLUS
CN 1-Piperidinebutanamide, N-hydroxy-α-[[methyl(4-methylphenyl)sulfonyl]amino]methyl]-β-(2-methylpropyl)-γ-oxo-, (αR,βR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-01-3 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-N-hydroxy-α-[[[4-methoxyphenyl]sulfonyl]methylamino]methyl]-γ-oxo-, (αR,βR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 244296-06-8 CAPLUS
CN 1-Piperidinebutanamide, α-[[[ethyl(4-methoxyphenyl)sulfonyl]amino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 206553-76-6 CAPLUS
CN 1-Piperidinebutanamide, α-[[[5-chloro-2-methoxyphenyl]sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 206553-77-7 CAPLUS
CN 1-Piperidinebutanamide, α-[[[4-(1,1-dimethylpropyl)phenyl]sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 206553-78-8 CAPLUS
CN 1-Piperidinebutanamide, α-[[[1,1'-biphenyl]-4-ylsulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 244296-07-9 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-α-[[[ethyl(4-methoxyphenyl)sulfonyl]amino]methyl]-N-hydroxy-γ-oxo-, (αR,βR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-09-1 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-α-[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-γ-oxo-, (αR,βR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 244296-10-4 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-α-[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-γ-oxo-, (αR,βR) - (9CI) (CA INDEX NAME)

CM 1

CRN 244296-09-1
CMF C29 H42 N4 O5 S

Absolute stereochemistry.





CM 2

CRN 76-05-1
CMF C2 H F3 O2


RN 244296-16-0 CAPLUS
CN 1-Piperidinebutanamide, α-[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]ethylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 244296-23-9 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-N-hydroxy-α-[[[methyl(8-quinolylsulfonyl)amino]methyl]-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-25-1 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-N-hydroxy-α-[[[methyl(1-naphthalenylsulfonyl)amino]methyl]-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-26-2 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-N-hydroxy-α-[[[5-isoquinolylsulfonyl]methylamino]methyl]-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 244296-17-1 CAPLUS

CN 1-Piperidinebutanamide, α-[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]ethylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)-, mono(trifluoroacetate) (salt) (9CI)
(CA INDEX NAME)

CM 1

CRN 244296-16-0
CMF C28 H42 N4 O5 S

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2


RN 244296-22-8 CAPLUS
CN 1-Piperidinebutanamide, α-[[[4-(chlorophenyl)sulfonyl]methylamino]methyl]-β-(cyclopentylmethyl)-N-hydroxy-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-27-3 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-α-[[[6-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 206553-91-5P 206553-96-0P
RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(Preparation of sulfonylaminoalkanediamides and related compds. as matrix metalloproteinase inhibitors)

RN 206553-91-5 CAPLUS
CN 1-Piperidinebutanoic acid, α-[3-[[[4-(methoxyphenyl)sulfonyl]methylamino]propyl]-β-(2-methylpropyl)-γ-oxo-, 1,1-dimethylethyl ester, (αS,βR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 206553-96-0 CAPLUS
CN 1-Piperidinebutanoic acid, α-[[[4-(methoxyphenyl)sulfonyl]methylamino]methyl]-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI)

L4 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
IT 182319-61-5P 182319-62-6P 182319-78-4P


182319-79-5P 182319-83-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(arylsulfonyl)valine hydroxamic acids and analogs as matrix metalloproteinase inhibitors or TNF production inhibitors)
RN 182319-61-5 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-{3-[[[(1R)-1-[(hydroxylamino)carbonyl]-2-methylpropyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 182319-62-6 CAPLUS
CN Butanamide, N-hydroxy-2-[[[(4-methoxyphenyl)sulfonyl][3-oxo-3-(1-piperazinyl)propyl]amino]-3-methyl-, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




• HCl

RN 182319-78-4 CAPLUS
CN Butanamide, N-hydroxy-2-[[[(4-methoxyphenyl)sulfonyl][3-(4-methyl-1-piperazinyl)-3-oxopropyl]amino]-3-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 182319-79-5 CAPLUS
CN Butanamide, N,3-dihydroxy-2-[[[(4-methoxyphenyl)sulfonyl][3-oxo-3-(1-piperidinyl)propyl]amino]-, (2R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 182319-83-1 CAPLUS
CN Cyclohexanecarboxamide, N-hydroxy-α-[[[(4-methoxyphenyl)sulfonyl][3-(4-methyl-1-piperazinyl)-3-oxopropyl]amino]-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN


IT 206553-57-3P 206553-72-2P 244296-01-3P
244296-09-1P 244296-22-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and biol. evaluation of non-peptidic matrix metalloproteinase inhibitors in relation to oral bioavailability)
RN 206553-57-3 CAPLUS
CN 1-Piperidinebutanamide, N-hydroxy-α-[[[(4-methoxyphenyl)sulfonyl]methylamino]methyl]-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 206553-72-2 CAPLUS
CN 1-Piperidinebutanamide, α-[[[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 244296-01-3 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-N-hydroxy-α-[[[(4-methoxyphenyl)sulfonyl]methylamino]methyl]-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 244296-09-1 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-α-[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 244296-22-8 CAPLUS
CN 1-Piperidinebutanamide, α-[[[4-chlorophenyl]sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-09-1 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-α-[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-10-4 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-α-[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-γ-oxo-, (αR,βR)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CH 1

CRN 244296-09-1
CMF C29 H42 N4 O5 S

Absolute stereochemistry.


IT 244296-01-3P 244296-06-8P 244296-07-9P
244296-09-1P 244296-10-4P 244296-16-0P
244296-17-1P 244296-22-8P 244296-23-9P
244296-25-1P 244296-26-2P 244296-28-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Preparation of hydroxamic acids and carboxylic acids as metalloproteinase inhibitors)
RN 244296-01-3 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-N-hydroxy-α-[[[4-methoxyphenyl]sulfonyl]methylamino]methyl]-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 244296-06-8 CAPLUS
CN 1-Piperidinebutanamide, α-[[[ethyl[(4-methoxyphenyl)sulfonyl]amino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-07-9 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-α-[[[ethyl[(4-methoxyphenyl)sulfonyl]amino]methyl]-N-hydroxy-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




CH 2

CRN 76-05-1
CMF C2 H F3 O2



RN 244296-16-0 CAPLUS
CN 1-Piperidinebutanamide, α-[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 244296-17-1 CAPLUS
CN 1-Piperidinebutanamide, α-[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CH 1

CRN 244296-16-0
 CHF C28 H42 N4 O5 S

Absolute stereochemistry.




CH 2

CRN 76-05-1
 CHF C2 H F3 O2



RN 244296-22-9 CAPLUS
 CN 1-Piperidinebutanamide, alpha-([[(4-chlorophenyl)sulfonyl]methylamino]methyl)-beta-(cyclopentylmethyl)-N-hydroxy-gamma-oxo-, (alpha,R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 244296-23-9 CAPLUS
 CN 1-Piperidinebutanamide, beta-(cyclopentylmethyl)-N-hydroxy-alpha-

L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (dimethylamino)-1-naphthalenyl)sulfonyl)methylamino]methyl]-N-hydroxy-gamma-oxo-, (alpha,R)-, mono(trifluoroacetate) (salt) (9CI)
 (CA INDEX NAME)

CH 1

CRN 244296-27-3
 CHF C29 H42 N4 O5 S

Absolute stereochemistry.



CH 2

CRN 76-05-1
 CHF C2 H F3 O2




IT 206553-96-0P
 RL: RCT (Reactant)/ SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of hydroxamic acids and carboxylic acids as metalloproteinase inhibitors)
 RN 206553-96-0 CAPLUS
 CN 1-Piperidinebutanoic acid, alpha-([[(4-methoxyphenyl)sulfonyl]methylamino]methyl)-beta-(2-methylpropyl)-gamma-oxo-, (alpha,R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 [[methyl(8-quinolyl)sulfonyl]amino]methyl]-gamma-oxo-, (alpha,R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 244296-25-1 CAPLUS
 CN 1-Piperidinebutanamide, beta-(cyclopentylmethyl)-N-hydroxy-alpha-([[(methyl(1-naphthalenyl)sulfonyl]amino]methyl)-gamma-oxo-, (alpha,R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 244296-26-2 CAPLUS
 CN 1-Piperidinebutanamide, beta-(cyclopentylmethyl)-N-hydroxy-alpha-([[(5-isoquinolyl)sulfonyl]methylamino]methyl)-gamma-oxo-, (alpha,R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-28-4 CAPLUS
 CN 1-Piperidinebutanamide, beta-(cyclopentylmethyl)-alpha-([[(6-


L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 206553-57-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of hydroxamic acids and carboxylic acids as metalloproteinase inhibitors)

RN 206553-57-3 CAPLUS
 CN 1-Piperidinebutanamide, N-hydroxy-alpha-([[(4-methoxyphenyl)sulfonyl]methylamino]methyl)-beta-(2-methylpropyl)-gamma-oxo-, (alpha,R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2007 ACS ON STN

IT 206553-54-0P 206553-55-1P 206553-57-3P
206553-63-1P 206553-64-2P 206553-66-4P
206553-67-5P 206553-68-6P 206553-70-0P
206553-72-2P 206553-74-4P 206553-75-5P
206553-76-6P 206553-77-7P 206553-78-8P
206553-81-3P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of hydroxamides as metalloproteinase inhibitors)

RN 206553-54-0 CAPLUS

CN 1-Piperidinebutanamide, N-hydroxy- α -[3-[[[4-methoxyphenyl]sulfonyl]methylamino]propyl]- β -(2-methylpropyl)- γ -oxo-, (aS, BR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 206553-55-1 CAPLUS

CN 1-Piperidinebutanamide, N-hydroxy- α -[2-[[[4-methoxyphenyl]sulfonyl]methylamino]ethyl]- β -(2-methylpropyl)- γ -oxo-, (aS, BR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 206553-57-3 CAPLUS

CN 1-Piperidinebutanamide, N-hydroxy- α -[[[4-methoxyphenyl]sulfonyl]methylamino]methyl]- β -(2-methylpropyl)- γ -oxo-, (aR, BR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



RN 206553-63-1 CAPLUS

CN 1-Piperidinebutanamide, α -[[[4-butoxyphenyl]sulfonyl]methylamino]methyl]-N-hydroxy- β -(2-methylpropyl)- γ -oxo-, (aR, BR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 206553-64-2 CAPLUS

CN 1-Piperidinebutanamide, α -[[[2-chloro-5-(trifluoromethyl)phenyl]sulfonyl]methylamino]methyl]-N-hydroxy- β -(2-methylpropyl)- γ -oxo-, (aR, BR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 206553-66-4 CAPLUS

CN 1-Piperidinebutanamide, α -[[[4-chloro-2,5-dimethylphenyl]sulfonyl]methylamino]methyl]-N-hydroxy- β -(2-methylpropyl)- γ -oxo-, (aR, BR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



RN 206553-67-5 CAPLUS

CN 1-Piperidinebutanamide, α -[[[2,5-dimethoxyphenyl]sulfonyl]methylamino]methyl]-N-hydroxy- β -(2-methylpropyl)- γ -oxo-, (aR, BR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 206553-68-6 CAPLUS

CN 1-Piperidinebutanamide, N-hydroxy- β -(2-methylpropyl)- α -[[methyl(8-quinoliny]sulfonyl]amino]methyl]- γ -oxo-, (aR, BR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 206553-70-0 CAPLUS

CN 1-Piperidinebutanamide, α -[[[4-chlorophenyl]sulfonyl]methylamino]methyl]-N-hydroxy- β -(2-methylpropyl)- γ -oxo-, (aR, BR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



RN 206553-72-2 CAPLUS

CN 1-Piperidinebutanamide, α -[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy- β -(2-methylpropyl)- γ -oxo-, (aR, BR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 206553-74-4 CAPLUS

CN 1-Piperidinebutanamide, N-hydroxy- α -[[methyl(2-naphthalenyl]sulfonyl]amino]methyl]- β -(2-methylpropyl)- γ -oxo-, (aR, BR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 206553-75-5 CAPLUS


CN 1-Piperidinebutanamide, α -[[[3,4-dichlorophenyl]sulfonyl]methylamino]methyl]-N-hydroxy- β -(2-methylpropyl)- γ -oxo-, (aR, BR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 206553-76-6 CAPLUS
 CN 1-Piperidinebutanamide, α-[[[(5-chloro-2-methoxyphenyl)sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 206553-77-7 CAPLUS
 CN 1-Piperidinebutanamide, α-[[[(4-[[[1,1-dimethylpropyl]phenyl]sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 206553-78-8 CAPLUS
 CN 1-Piperidinebutanamide, α-[[[(1,1'-biphenyl)-4-ylsulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Absolute stereochemistry.



RN 206553-81-3 CAPLUS
 CN 1-Piperidinebutanamide, N-hydroxy-α-[[methyl[(4-methylphenyl)sulfonyl]amino]methyl]-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 206553-91-5P 206553-96-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of hydroxamides as metalloproteinase inhibitors)

RN 206553-91-5 CAPLUS
 CN 1-Piperidinebutanoic acid, α-[[[(4-methoxyphenyl)sulfonyl]methylamino]methyl]-β-(2-methylpropyl)-γ-oxo-, 1,1-dimethylethyl ester, (αS,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 206553-96-0 CAPLUS
 CN 1-Piperidinebutanoic acid, α-[[[(4-methoxyphenyl)sulfonyl]methylamino]methyl]-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


IT 203732-09-6P 203732-45-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of arylsulfonylamino hydroxamic acid derivs. as inhibitors of matrix metalloproteinase and production of tumor necrosis factor (TNF))

RN 203732-09-6 CAPLUS
 CN 4-Piperidinecarboxylic acid, 1-[3-[[1-[(hydroxylamino)carbonyl]-3-phenylpropyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 203732-45-0 CAPLUS
 CN Benzenepropanamide, 4-chloro-N-hydroxy-α-[[[(4-methoxyphenyl)sulfonyl][3-[4-(methylamino)-1-piperidinyl]-3-oxopropyl]amino]- (9CI) (CA INDEX NAME)



IT 203731-89-9P 203731-90-2P 203731-91-3P
 203731-92-4P 203731-93-5P 203731-94-6P
 203731-95-7P 203731-96-8P 203731-97-9P
 203731-98-0P 203732-00-7P 203732-01-8P
 203732-02-9P 203732-03-0P 203732-05-2P

L4 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


203732-06-3P 203732-07-4P 203732-08-5P
203732-10-9P 203732-11-0P 203732-12-1P
203732-13-2P 203732-14-3P 203732-15-4P
203732-16-5P 203732-17-6P 203732-18-7P
203732-19-8P 203732-20-1P 203732-21-2P
203732-22-3P 203732-23-4P 203732-24-5P
203732-25-6P 203732-26-7P 203732-27-8P
203732-28-9P 203732-29-0P 203732-30-3P
203732-31-4P 203732-32-5P 203732-33-6P
203732-34-7P 203732-35-8P 203732-36-9P
203732-37-0P 203732-38-1P 203732-39-2P
203732-40-5P 203732-41-6P 203732-42-7P
203732-43-8P 203732-44-9P 203732-46-1P
203732-47-2P 203732-48-3P 203732-49-4P
203732-50-7P 203732-51-8P 203732-52-9P
203732-53-0P 203732-54-1P 203732-58-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of arylsulfonylamino hydroxamic acid derivs. as inhibitors of matrix metalloproteinase and prodn. of tumor necrosis factor (TNF))

RN 203731-89-9 CAPLUS

CN Carbamic acid, [1-[3-[[1-(cyclohexyl)-2-(hydroxyamino)-2-oxoethyl]-(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-piperidinylmethyl-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 203731-90-2 CAPLUS

CN Butanamide, 2-[[3-[4-(acetyloxy)-1-piperidinyl]-3-oxopropyl]-(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-3-methyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 203731-94-6 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[3-[[1-[(hydroxyamino)carbonyl]-2-methylpropyl]-(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 203731-95-7 CAPLUS

CN 1-Piperazineacetic acid, 4-[3-[[1-[(hydroxyamino)carbonyl]-2-methylpropyl]-(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 203731-96-8 CAPLUS

CN Carbamic acid, [1-[3-[[1-[(hydroxyamino)carbonyl]-3-methylbutyl]-(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-piperidinylmethyl-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 203731-91-3 CAPLUS

CN Butanoic acid, 1-[3-[[1-[(hydroxyamino)carbonyl]-2-methylpropyl]-(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-piperidinyl ester, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 203731-92-4 CAPLUS

CN Butanamide, 2-[[3-[4-(benzoyloxy)-1-piperidinyl]-3-oxopropyl]-(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-3-methyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 203731-93-5 CAPLUS

CN Butanamide, N-hydroxy-2-[[3-[4-(hydroxy-1-piperidinyl)-3-oxopropyl]-(4-methoxyphenyl)sulfonyl]amino]-3-methyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 203731-97-9 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[3-[[1-[(hydroxyamino)carbonyl]-3-methylbutyl]-(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 203731-98-0 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[3-[[1-[(hydroxyamino)carbonyl]pentyl]-(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 203732-00-7 CAPLUS


CN Carbamic acid, [1-[3-[[1-[(hydroxyamino)carbonyl]-3,3-dimethylbutyl]-(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-piperidinylmethyl-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 203732-01-8 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-[(hydroxyamino)carbonyl]-3,3-dimethylbutyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 203732-02-9 CAPLUS
CN Cyclohexanecarboxamide, N-hydroxy-α-[[3-(4-hydroxy-1-piperidinyl)-3-oxopropyl][(4-methoxyphenyl)sulfonyl]amino]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 203732-06-3 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[2-(hydroxyamino)-2-oxo-1-(phenylmethyl)ethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 203732-07-4 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-[(4-fluorophenyl)methyl]-2-(hydroxyamino)-2-oxoethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 203732-08-5 CAPLUS
CN Carbamic acid, 1-[3-[[1-[(1,1-dimethylethoxy)methyl]-2-(hydroxyamino)-2-oxoethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-piperidinylmethyl-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 203732-03-0 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-cyclohexyl-2-(hydroxyamino)-2-oxoethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 203732-05-2 CAPLUS
CN Carbamic acid, 1-[3-[[2-(hydroxyamino)-2-oxo-1-(phenylmethyl)ethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-piperidinylmethyl-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 203732-09-9 CAPLUS
CN Carbamic acid, 1-[3-[[1-[(1,1-dimethylethoxy)methyl]-2-(hydroxyamino)-2-oxoethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-piperidinylmethyl-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 203732-11-0 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-[(1,1-dimethylethoxy)methyl]-2-(hydroxyamino)-2-oxoethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 203732-12-1 CAPLUS
CN Carbamic acid, 1-[3-[[1-[(1-cyclohexylmethyl)-2-(hydroxyamino)-2-oxoethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-piperidinylmethyl-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 203732-13-2 CAPLUS
CN 4-(Piperidinecarboxylic acid, 1-[[3-[[1-(cyclohexylmethyl)-2-(hydroxyamino)-2-oxoethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 203732-14-3 CAPLUS
CN 4-(Piperidinecarboxylic acid, 1-[[3-[[2-(hydroxyamino)-1-(2-naphthalenylmethyl)-2-oxoethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 203732-15-4 CAPLUS
CN Cyclohexanecarboxamide, N-hydroxy-α-[[[(4-methoxyphenyl)sulfonyl][3-[(4-methylamino)-1-piperidinyl]-3-oxopropyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 203732-16-5 CAPLUS
CN Butanamide, N-hydroxy-2-[[[(4-methoxyphenyl)sulfonyl][3-[(4-methylamino)-1-piperidinyl]-3-oxopropyl]amino]-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 203732-17-6 CAPLUS
CN Pentanamide, N-hydroxy-2-[[[(4-methoxyphenyl)sulfonyl][3-[(4-methylamino)-1-piperidinyl]-3-oxopropyl]amino]-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 203732-18-7 CAPLUS
CN Hexanamide, N-hydroxy-2-[[[(4-methoxyphenyl)sulfonyl][3-[(4-methylamino)-1-piperidinyl]-3-oxopropyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 203732-19-8 CAPLUS
CN Pentanamide, N-hydroxy-2-[[[(4-methoxyphenyl)sulfonyl][3-[(4-methylamino)-1-piperidinyl]-3-oxopropyl]amino]-4,4-dimethyl-, monohydrochloride (9CI)




● HCl

RN 203732-20-1 CAPLUS
CN Benzenehexanamide, N-hydroxy-α-[[[(4-methoxyphenyl)sulfonyl][3-[(4-methylamino)-1-piperidinyl]-3-oxopropyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 203732-21-2 CAPLUS
CN Benzenehexanamide, N-hydroxy-α-[[[(4-methoxyphenyl)sulfonyl][3-[(4-methylamino)-1-piperidinyl]-3-oxopropyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 203732-22-3 CAPLUS
 CN Benzenebutanamide, N-hydroxy-α-[[4-(methoxyphenyl)sulfonyl][3-[4-(methylamino)-1-piperidinyl]-3-oxopropyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 203732-23-4 CAPLUS
 CN Propanamide, 3-[(1,1-dimethylethoxy)-N-hydroxy-2-[[4-(methoxyphenyl)sulfonyl][3-[4-(methylamino)-1-piperidinyl]-3-oxopropyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 203732-24-5 CAPLUS
 CN Cyclohexanepropanamide, N-hydroxy-α-[[4-(methoxyphenyl)sulfonyl][3-[4-(methylamino)-1-piperidinyl]-3-oxopropyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 203732-25-6 CAPLUS
 CN 2-Naphthalenepropanamide, N-hydroxy-α-[[4-(methoxyphenyl)sulfonyl][3-[4-(methylamino)-1-piperidinyl]-3-oxopropyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 203732-26-7 CAPLUS
 CN 4-Piperidinecarboxylic acid, 1-[3-[[1-cyclohexyl-2-(hydroxyamino)-2-oxoethyl][4-(methoxyphenyl)sulfonyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 203732-27-8 CAPLUS
 CN 4-Piperidinecarboxylic acid, 1-[3-[[1-(hydroxyamino)carbonyl]-2-methylpropyl][4-(methoxyphenyl)sulfonyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 203732-28-9 CAPLUS
 CN 1-Piperazineacetic acid, 4-[3-[[1-(hydroxyamino)carbonyl]-2-methylpropyl][4-(methoxyphenyl)sulfonyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 203732-29-0 CAPLUS
 CN 4-Piperidinecarboxylic acid, 1-[3-[[1-(hydroxyamino)carbonyl]-2-methylpropyl][4-(methoxyphenyl)sulfonyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 203732-30-3 CAPLUS
 CN 4-Piperidinecarboxylic acid, 1-[3-[[1-(hydroxyamino)carbonyl]pentyl][4-(methoxyphenyl)sulfonyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 203732-31-4 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[[3-[[1-[(hydroxyamino)carbonyl]-3-dimethylbutyl] [(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 203732-32-5 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[[3-[[2-(hydroxyamino)-2-oxo-1-(phenylmethyl)ethyl] [(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 203732-33-6 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[[3-[[1-[(4-fluorophenyl)methyl]-2-(hydroxyamino)-2-oxoethyl] [(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 203732-37-0 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[[3-[[2-(hydroxyamino)-1-(2-naphthalenylmethyl)-2-oxoethyl] [(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 203732-38-1 CAPLUS
CN Butanamide, N-hydroxy-2-[[3-[[4-(2-hydroxyethyl)-1-piperazinyl]-3-oxopropyl] [(4-methoxyphenyl)sulfonyl]amino]-3-methyl-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 203732-34-7 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[[3-[[1-[(hydroxyamino)carbonyl]-3-phenylpropyl] [(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 203732-35-8 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[[3-[[1-[(1,1-dimethylethoxy)methyl]-2-(hydroxyamino)-2-oxoethyl] [(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 203732-36-9 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[[3-[[1-[(cyclohexylmethyl)-2-(hydroxyamino)-2-oxoethyl] [(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 203732-39-2 CAPLUS
CN Butanamide, 2-[[3-[[4-(dimethylamino)-1-piperidinyl]-3-oxopropyl] [(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-3-methyl-, (9CI) (CA INDEX NAME)



RN 203732-40-5 CAPLUS
CN Butanamide, N-hydroxy-2-[[3-[[4-(3-hydroxypropyl)-1-piperazinyl]-3-oxopropyl] [(4-methoxyphenyl)sulfonyl]amino]-3-methyl-, (9CI) (CA INDEX NAME)




RN 203732-41-6 CAPLUS
CN Butanamide, 2-[[3-[[1,4'-bipiperidin-1'-yl]-3-oxopropyl] [(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 203732-42-7 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-[(hydroxyamino)carbonyl]-2-methylpropyl][(4-phenoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 203732-43-8 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-[(hydroxyamino)carbonyl]-2-methylpropyl][(4-phenoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 203732-44-9 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-[(hydroxyamino)carbonyl]-2-methylpropyl][(4-phenoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)


RN 203732-48-3 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 2-[4-[3-[[1-[(hydroxyamino)carbonyl]-2-methylpropyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)




RN 203732-49-4 CAPLUS
CN Butanamide, 2-[[3-[4-[2-(benzoyloxy)ethyl]-1-piperazinyl]-3-oxopropyl][(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-3-methyl- (9CI) (CA INDEX NAME)




RN 203732-50-7 CAPLUS
CN Cyclohexanecarboxamide, N-hydroxy-2-[[3-[4-[2-(hydroxyethyl)-1-piperazinyl]-3-oxopropyl][(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-3-methyl- (9CI) (CA INDEX NAME)




RN 203732-51-8 CAPLUS
CN Butanamide, N-hydroxy-2-[[3-[5-(2-hydroxyethyl)-2,5-




RN 203732-46-1 CAPLUS
CN Cyclohexanecarboxamide, N-hydroxy-2-[[3-[4-[2-(hydroxyethyl)-1-piperazinyl]-3-oxopropyl][(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-3-methyl- (9CI) (CA INDEX NAME)




RN 203732-47-2 CAPLUS
CN Butanamide, N-hydroxy-2-[[3-[4-[2-(hydroxyethyl)-1-piperazinyl]-3-oxopropyl][(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-3-methyl- (9CI) (CA INDEX NAME)




RN 203732-52-9 CAPLUS
CN Butanamide, N-hydroxy-2-[[3-[4-[2-(hydroxyethyl)-1-piperazinyl]-3-oxopropyl][(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-3-methyl- (9CI) (CA INDEX NAME)




RN 203732-52-9 CAPLUS
CN Butanamide, N-hydroxy-2-[[3-[4-[2-(hydroxyethyl)-1-piperazinyl]-3-oxopropyl][(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-3-methyl- (9CI) (CA INDEX NAME)




RN 203732-53-0 CAPLUS
CN Cyclohexanecarboxamide, N-hydroxy-2-[[3-[4-[2-(hydroxyethyl)-1-piperazinyl]-3-oxopropyl][(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-3-methyl- (9CI) (CA INDEX NAME)




RN 203732-54-1 CAPLUS
CN Butanamide, N-hydroxy-2-[[3-[4-[2-(hydroxyethyl)-1-piperazinyl]-3-oxopropyl][(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-3-methyl- (9CI) (CA INDEX NAME)




RN 203732-58-5 CAPLUS
CN 2-Piperazinecarboxylic acid, 4-[3-[[1-[(hydroxyamino)carbonyl]-2-methylpropyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)




IT 203732-80-3 203732-81-4 203732-82-5
203732-83-6 203732-84-7 203732-85-8
203732-86-9 203732-88-1 203732-89-2
203732-90-5 203732-91-6 203732-92-7
203732-93-8 203732-94-9 203732-95-0
203732-96-1 203732-97-2 203732-98-3
203732-99-4 203733-00-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of arylsulfonylamino hydroxamic acid derivs, as inhibitors of matrix metalloproteinase and production of tumor necrosis factor (TNF))
RN 203732-80-3 CAPLUS
CN Carbanic acid, [1-[3-[[1-cyclohexyl-2-(hydroxyamino)-2-oxoethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 203732-84-7 CAPLUS
CN Carbanic acid, [1-[3-[[1-[(hydroxyamino)carbonyl]-3,3-dimethylbutyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 203732-85-8 CAPLUS
CN Carbanic acid, [1-[3-[[1-[(hydroxyamino)carbonyl]-2-oxo-1-(phenylmethyl)ethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 203732-86-9 CAPLUS
CN Carbanic acid, [1-[3-[[1-[(hydroxyamino)carbonyl]-3-phenylpropyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 203732-81-4 CAPLUS
CN Carbanic acid, [1-[3-[[1-[(hydroxyamino)carbonyl]-2-methylpropyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 203732-82-5 CAPLUS
CN Carbanic acid, [1-[3-[[1-[(hydroxyamino)carbonyl]-3-methylbutyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 203732-83-6 CAPLUS
CN Carbanic acid, [1-[3-[[1-[(hydroxyamino)carbonyl]pentyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 203732-88-1 CAPLUS
CN Carbanic acid, [1-[3-[[1-[(1,1-dimethylethoxy)methyl]-2-(hydroxyamino)-2-oxoethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 203732-89-2 CAPLUS
CN Carbanic acid, [1-[3-[[1-(cyclohexylmethyl)-2-(hydroxyamino)-2-oxoethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 203732-90-5 CAPLUS
CN Carbanic acid, [1-[3-[[1-[(hydroxyamino)carbonyl]-2-oxo-1-(phenylmethyl)ethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 203732-91-6 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-[(hydroxyamino)carbonyl]-2-methylpropyl][4-(methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester (9CI), (CA INDEX NAME)




RN 203732-92-7 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-[(hydroxyamino)carbonyl]-3-methylbutyl] [(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 203732-93-8 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-[(hydroxyamino)carbonyl]pentyl][4-methoxyphenyl]sulfonyl]amino]-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 203732-97-2 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-[(hydroxyamino)carbonyl]-3-phenylpropyl]][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 203732-98-3 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-{{[1-[(1,1-dimethylethoxy)methyl]-2-(hydroxymethyl)-2-oxoethyl]{{[4-methoxyphenyl)sulfonyl]amino}-1-oxopropyl}-ethyl ester (9CI) (CA INDEX NAME)




RN 203732-99-4 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-(cyclohexylmethyl)-2-(hydroxyamino)-2-oxoethyl][4-methoxyphenyl]sulfonyl]amino]-1-oxopropyl]-, ethyl ester (9CI) [CA INDEX NAME]




RN 203732-94-9 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-[(hydroxyamino)carbonyl]-3,3-dimethylbutyl][4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, (ethyl ester) (9CI) (CA INDEX NAME)




RN 203732-95-0 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[2-(hydroxyamino)-2-oxo-1-phenylethyl]ethyl][4-methoxyphenyl]sulfonyl]amino]-1-oxopropyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 203732-96-1 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-[(4-fluorophenyl)methyl]-2-(hydroxyamino)-2-oxoethyl][4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester (SC1) (CA INDEX NAME)




RN 203733-00-0 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[2-(hydroxyamino)-1-(2-naphthalenylmethyl)-2-oxoethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester (9CI) [CA INDEX NAME]




IT	203732-68-7P	203732-69-8P	203732-70-1P
	203732-71-2P	203732-72-3P	203732-73-4P
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of arylsulfonylaminohydroxamic acid derivs. as inhibitors of matrix metalloproteinase and production of tumor necrosis factor (TNF))		
RN	203732-68-7 CAPLUS		
CN	Cyclohexanecarboxylic acid, α -[3-[4-[[[1,1- dimethyl-4-oxo-1,2,3,4-tetrahydropyridin-3-yl]propyl]-4- methoxyphenyl]sulfonyl]amino]-, phenylmethyl ester, (R)- (9CI) (CA INDEX NAME)		

Absolute stereochemistry.





RN 203732-69-8 CAPLUS
 CN Cyclohexanecarboxylic acid, α-[3-[4-[[[1,1-dimethylethoxy]carbonyl]methylamino]-1-piperidinyl]-3-oxopropyl] [(4-methoxyphenyl)sulfonyl]amino]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 203732-70-1 CAPLUS
 CN Carbamic acid, [1-[3-[[[1-cyclohexyl-2-oxo-2-[(phenylmethoxy)amino]ethyl] [(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 203732-71-2 CAPLUS
 CN D-Valine, N-[3-[4-(2-hydroxyethyl)-1-piperazinyl]-3-oxopropyl]-N-[(4-methoxyphenyl)sulfonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 203732-72-3 CAPLUS
 CN D-Valine, N-[3-[4-(2-hydroxyethyl)-1-piperazinyl]-3-oxopropyl]-N-[(4-methoxyphenyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 203732-73-4 CAPLUS
 CN Butanamide, 2-[[3-[4-(2-hydroxyethyl)-1-piperazinyl]-3-oxopropyl] [(4-methoxyphenyl)sulfonyl]amino]-3-methyl-N-(phenylmethoxy)-, (R)- (9CI) (CA INDEX NAME)

IT 182319-61-5P 182319-62-6P 182319-78-4P
 182319-79-5P 182319-83-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Preparation of (arylsulfonylamino)hydroxamates as matrix metalloproteinase

and tumor necrosis factor production inhibitors)


RN 182319-61-5 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[3-[[[1R]-1-[(hydroxyamino)carbonyl]-2-methylpropyl] [(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 182319-62-6 CAPLUS
 CN Butanamide, N-hydroxy-2-[[[4-methoxyphenyl)sulfonyl] [3-oxo-3-(1-piperazinyl)propyl]amino]-3-methyl-, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 182319-78-4 CAPLUS
 CN Butanamide, N-hydroxy-2-[[[4-methoxyphenyl)sulfonyl] [3-(4-methyl-1-piperazinyl)-3-oxopropyl]amino]-3-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 182319-79-5 CAPLUS
CN Butanamide, N,3-dihydroxy-2-[[[(4-methoxyphenyl)sulfonyl][3-oxo-3-(1-piperidinyl)propyl]amino]-, (2R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 182319-83-1 CAPLUS
CN Cyclohexanecarboxamide, N-hydroxy-α-[[[(4-methoxyphenyl)sulfonyl][3-(4-methyl-1-piperazinyl)-3-oxopropyl]amino]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 172738-38-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonamide derivs. as aspartyl protease inhibitors)
RN 172738-38-4 CAPLUS
CN 1-Piperazinecarboxylic acid, 3-[[[(1,1-dimethylethyl)amino]carbonyl]-4-[(3S)-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-oxobutyl]-, phenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d his

(FILE 'HOME' ENTERED AT 17:28:53 ON 09 JUL 2007)

FILE 'REGISTRY' ENTERED AT 17:29:02 ON 09 JUL 2007

L1 STRUCTURE UPLOADED
L2 29 S L1
L3 492 S L1 FULL

FILE 'CAPLUS' ENTERED AT 17:30:11 ON 09 JUL 2007

L4 15 S L3

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	85.16	257.92
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-11.70	-11.70

STN INTERNATIONAL LOGOFF AT 17:37:44 ON 09 JUL 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJHM1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 3 MAR 16 CASREACT coverage extended
NEWS 4 MAR 20 MARPAT now updated daily
NEWS 5 MAR 22 LWPI reloaded
NEWS 6 MAR 30 RDISCLOSURE reloaded with enhancements
NEWS 7 APR 02 JICST-EPLUS removed from database clusters and STN
NEWS 8 APR 30 GENBANK reloaded and enhanced with Genome Project ID field
NEWS 9 APR 30 CHEMCATS enhanced with 1.2 million new records
NEWS 10 APR 30 CA/CAPLUS enhanced with 1870-1889 U.S. patent records
NEWS 11 APR 30 INPADOC replaced by INPADOCDB on STN
NEWS 12 MAY 01 New CAS web site launched
NEWS 13 MAY 08 CA/CAPLUS Indian patent publication number format defined
NEWS 14 MAY 14 RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 15 MAY 21 BIOSIS reloaded and enhanced with archival data
NEWS 16 MAY 21 TOXCENTER enhanced with BIOSIS reload
NEWS 17 MAY 21 CA/CAPLUS enhanced with additional kind codes for German patents